PAVmed Inc. (PAVM)
Automate Your Wheel Strategy on PAVM
With Tiblio's Option Bot, you can configure your own wheel strategy including PAVM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PAVM
- Rev/Share 0.1436
- Book/Share 2949.8064
- PB 0.0002
- Debt/Equity 0.2053
- CurrentRatio 0.3719
- ROIC -0.099
- MktCap 10686333.0
- FreeCF/Share -115.4107
- PFCF -0.0067
- PE 0.1159
- Debt/Assets 0.1749
- DivYield 0
- ROE 0.0066
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 1
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
Published: June 18, 2025 by: PRNewsWire
Sentiment: Neutral
Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK , June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, integrated esophageal precancer testing program using Lucid Diagnostics' EsoGuard® Esophageal DNA Test. Lucid will partner with Hoag to offer EsoGuard testing across its digestive health, primary care, and concierge medicine …
Read More
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – James NEW YORK , June 3, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris has entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J.
Read More
PAVmed Inc. (PAVM) Q1 2025 Earnings Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
PAVmed Inc. (NASDAQ:PAVM ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of Investor Relations Lishan Aklog - Chairman and Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Jeremy Pearlman - Maxim Group Edward Woo - Ascendiant Capital Operator Good morning, and welcome to the PAVmed's First Quarter 2025 Business Update Conference Call. At this time, all lines are in a listen-only mode.
Read More
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D.
Read More
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
PAVmed (PAVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
Published: April 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock, including 1,875,000 shares issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a public offering price of $1.20 per share. The total net proceeds from the offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $16.1 million.
Read More
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Published: April 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D. , Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 11:00 AM EDT.
Read More
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK , March 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced a campaign, entitled "Embrace the Future", designed to showcase its groundbreaking EsoCheck® Esophageal Cell Collection Device, with Collect+Protect™ Technology, to gastroenterologists and the broader medical community. The campaign will coincide with Esophageal Cancer Awareness Month this April and will be prominently featured at Digestive Disease Week (DDW) …
Read More
PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Neutral
PAVmed Inc. (NASDAQ:PAVM ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Jeremy Pearlman - Maxim Group Matthew Park - Cantor Fitzgerald Ed Woo - Ascendiant Capital Operator Good morning, and welcome to PAVmed's Fourth Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode.
Read More
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy NEW YORK , March 20, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that a recent update to the National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) focused on Esophageal and Esophagogastric Junction Cancers (Version 1.2025) has added a new section on esophageal precancer (Barrett's Esophagus or BE) screening. The NCCN Guidelines® now reference professional …
Read More
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
Published: March 10, 2025 by: PRNewsWire
Sentiment: Neutral
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Monday, March 24, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D.
Read More
PAVmed and Subsidiary Veris Health Complete Private Placement Financing
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
Gross proceeds of approximately $2.4 million from sale of PAVmed securities priced at-the-market and Veris common stock priced at a $35 million pre-money valuation NEW YORK , Feb. 24, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary, Veris Health Inc, ("Veris") today announced that the companies have completed a $2.37 million private placement financing as detailed in Form 8-K filed with the SEC on February 21, 2025. Accredited investors purchased PAVmed securities priced at-the-market and shares of …
Read More
About PAVmed Inc. (PAVM)
- IPO Date 2016-07-27
- Website https://www.pavmed.com
- Industry Medical - Devices
- CEO Lishan Aklog
- Employees 39